Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that loss of function of DUSP22 in PCa cells leads to aberrant activation of both EGFR-ERKs and AR signaling and ultimately progression of PCa, supporting the potential for novel therapeutic design of harnessing DUSP22 in the treatment of PCa.-Lin, H.-P., Ho, H.-M., Chang, C.-W., Yeh, S.-D., Su, Y.-W., Tan, T.-H., Lin, W.-J.
|
31693867 |
2019 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Preclinical studies revealed remarkable efficacies of MAPK/ERK inhibitors in suppressing enzalutamide-resistant prostate cancer.
|
30952632 |
2019 |
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The upregulation of parts of the EphB2 and Src pathways also predicts poor prognosis in the prostate cancer patient cohort of The Cancer Genome Atlas.
|
31805710 |
2019 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway.
|
30142541 |
2018 |
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We have found that the nuclear ERK-selective phosphatase DUSP5 is downregulated in colorectal tumours and cell lines, as previously observed in gastric and prostate cancer.
|
29379130 |
2018 |
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y-Box Binding Protein-1 Expression in Prostate Cancer.
|
27699813 |
2017 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
In conclusion, our findings have identified critical molecular mechanisms involving ERK-mediated ERG activation that could be exploited for therapeutic intervention in ERG-positive prostate cancers.
|
28887309 |
2017 |
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
With inhibition of p38, ERK, and JNK, the TSP-2-induced cell migration and MMP-2 expression were abolished, indicating that the TSP-2's effect on PCa is MAPK dependent.
|
28122633 |
2017 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Together, we have identified an association of genetic variants and genes in the RTK/ERK pathway with prostate cancer aggressiveness, and highlighted the potential importance of CCND2 in prostate cancer susceptibility and tumor progression to metastasis.
|
28674394 |
2017 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
We further demonstrate that MEK/ERK and PI3K-C2β are required for PCa cell invasion but not proliferation.
|
26983806 |
2016 |
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of lncRNA-ATB exerts mitogenic and EMT effects of prostate cancer via activation of ERK and PI3K/AKT signaling pathways.
|
27176634 |
2016 |
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Finally, the results demonstrated that AQP3 upregulated matrix metalloproteinase‑3 (MMP‑3) expression and secretion in prostate cancer cells via activation of the ERK pathway.
|
25515250 |
2015 |
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
MEK/ERK inhibitors are also in clinical trials and the importance of pRB inactivation in prostate cancer is becoming more widely recognized.
|
25070358 |
2014 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our findings indicate that oncogenic ETS rearrangements cause a cell migration gene expression program to switch from RAS/ERK control to PI3K/AKT control and provide a possible explanation for the high frequency of PTEN, but not RAS/RAF mutations in prostate cancer.
|
24642271 |
2014 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
According to our previous study, the RTK/ERK pathway containing nearly 40 genes was associated with PCa risk.
|
24177231 |
2014 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results indicate that CLIC1 could regulate prostate cancer cell proliferation and migration by regulating the mitogen-activated protein kinase (MAPK)/ERK pathway and offers a candidate molecular target for prostate cancer prevention and therapy.
|
25279971 |
2014 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
The role of eotaxin-1 and the CCR3-ERK pathway in prostate cancer cell invasion was assessed by invasion and migration assays.
|
24604010 |
2014 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
The results indicate that the RTK/ERK pathway under natural selection is a key link in PCa risk.
|
24223781 |
2013 |
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity.
|
23538858 |
2013 |
Malignant neoplasm of prostate
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
In functional assays, SPRED2 overexpression reduced ERK phosphorylation and inhibited prostate cancer cell proliferation and migration in response to different growth factors and full-media stimulation (P<0.001).
|
23169297 |
2013 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Concurrent activation of RAS/ERK and PI3K/AKT pathways is implicated in prostate cancer progression.
|
23434594 |
2013 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion.
|
22200661 |
2012 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Inhibition of TGF-β in an TRAMP-C2 CaP model in C57BL/6 mice using 1D11 was associated with downregulation of DNMTs and p-ERK and impairment in tumor growth.
|
21980391 |
2011 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
RKIP has been shown to regulate the RAS-RAF-MEK-ERK kinase cascade acting as modulator of apoptosis and metastasis in prostate cancer.
|
20853079 |
2011 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Single marker-based logistical regression analyses revealed seven EphB2 SNPs showing statistically significant association with prostate cancer risk in our population.
|
21603658 |
2011 |